155,697 Shares in United Therapeutics Corporation $UTHR Purchased by Wick Capital Partners LLC

Wick Capital Partners LLC acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 155,697 shares of the biotechnology company’s stock, valued at approximately $75,863,000. United Therapeutics makes up about 5.5% of Wick Capital Partners LLC’s holdings, making the stock its 5th biggest holding.

Other hedge funds have also added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its stake in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the period. Jump Financial LLC bought a new position in United Therapeutics during the second quarter valued at $277,000. Cerity Partners LLC increased its position in United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia increased its position in United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after buying an additional 105 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on UTHR. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Cantor Fitzgerald increased their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Finally, Raymond James Financial began coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,540,358.40. The trade was a 34.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 644,468 shares of company stock valued at $364,004,497. 8.60% of the stock is owned by company insiders.

United Therapeutics Price Performance

United Therapeutics stock opened at $536.59 on Friday. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The business has a fifty day moving average price of $565.37 and a 200-day moving average price of $523.32. The firm has a market capitalization of $22.78 billion, a P/E ratio of 19.81, a PEG ratio of 1.80 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.63 earnings per share. Sell-side analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.